CJC-1295 + Ipamorelin: The Complete Research Guide to the Most Studied Growth Hormone Stack
- VPL Research Team
- 6 days ago
- 9 min read
CJC-1295 + Ipamorelin: The Complete Research Guide to the Most Studied Growth Hormone Stack
Published by VPL Research Team Category: Metabolics | Research Peptides
Research Disclaimer: This article is for educational and informational purposes only. CJC-1295 and Ipamorelin are research compounds not approved by the FDA for human use. All content is intended strictly for researchers and scientists. For questions about human health or personal use, consult a licensed healthcare provider. Resources: PubMed | ClinicalTrials.gov | Examine.com
If you've been researching growth hormone-related peptides for more than five minutes, you've almost certainly come across the names CJC-1295 and Ipamorelin — often mentioned together, almost always in the same breath. This pairing has become the most studied growth hormone secretagogue combination in the peptide research space, and for a very specific reason: the two compounds work through completely different biological mechanisms that happen to be perfectly complementary to each other.
Understanding why requires a quick look at how your body naturally produces growth hormone — and why researchers consider this two-peptide approach to be more physiologically aligned than either compound alone.
Vitality Peptide Labs supplies research-grade [CJC-1295 + Ipamorelin](CJC+IPAMORELIN) verified by independent third-party Certificate of Analysis. Every batch is manufactured in GMP-certified facilities.
How Your Body Normally Produces Growth Hormone
Before getting into what these two peptides do, it helps to understand the system they work within. Think of your body's growth hormone production like a factory with two separate control rooms.
Control Room 1 — The Hypothalamus: This part of the brain produces Growth Hormone-Releasing Hormone (GHRH) — the "go" signal. When GHRH is released, it travels to the pituitary gland and tells it to produce and release growth hormone.
Control Room 2 — The Stomach: Your stomach produces a hormone called ghrelin — sometimes called the "hunger hormone." Ghrelin also signals the pituitary gland, but through a completely separate pathway. It binds to a different receptor — the GHS-R1a (Growth Hormone Secretagogue Receptor) — and amplifies the pituitary's response to the GHRH signal.
The Stop Signal: There's also somatostatin — the "stop" signal — also produced by the hypothalamus, which periodically suppresses GH release. This is why growth hormone is released in pulses rather than continuously. The natural rhythm of GH release — multiple bursts throughout the day with the largest occurring during deep sleep — is the result of this ongoing push-pull between GHRH, ghrelin, and somatostatin.
The Key Insight: When GHRH and ghrelin work together, the pituitary doesn't just release the sum of what each signal would produce individually — it releases significantly more. Research has consistently shown that simultaneous activation of both the GHRH receptor and the ghrelin receptor produces a synergistic GH response — greater than either pathway can achieve alone. This is the fundamental scientific rationale for studying CJC-1295 and Ipamorelin as a combination.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of GHRH — the body's own "go" signal for growth hormone production. It is a 30-amino acid modified peptide that works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating them to synthesize and release growth hormone.
The critical difference between CJC-1295 and the body's natural GHRH is stability. Natural GHRH breaks down rapidly — within minutes in the bloodstream — which severely limits its practical use as a research tool. CJC-1295 was engineered with four strategic amino acid substitutions that make it resistant to the enzymes that degrade natural GHRH, dramatically extending its active duration.
CJC-1295 with DAC vs. without DAC — An Important Distinction
CJC-1295 exists in two forms that behave quite differently:
CJC-1295 with DAC (Drug Affinity Complex) — a chemical modification that allows the peptide to bind to albumin in the bloodstream, extending its half-life to approximately 6–8 days. A single injection maintains elevated GH stimulation for up to a week. This produces a sustained, continuous GH elevation rather than a pulsatile one.
CJC-1295 without DAC (also called Modified GRF 1-29) — a shorter-acting version with a half-life of approximately 30 minutes. This produces discrete GH pulses that more closely mimic the body's natural pulsatile GH secretion pattern. Most researchers studying the CJC-1295 + Ipamorelin combination use the without-DAC form specifically because preserving pulsatile GH release is considered more physiologically relevant.
In plain English: CJC-1295 essentially tells the pituitary "make more growth hormone and release bigger pulses." The without-DAC version delivers this message in short, sharp bursts that work with the body's natural rhythm rather than overriding it.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide — just five amino acids — that was developed by Novo Nordisk in the late 1990s. It works as a selective agonist of the ghrelin receptor (GHS-R1a) — meaning it mimics the action of ghrelin, the body's natural "amplifier" of growth hormone release.
What makes Ipamorelin stand out from earlier growth hormone-releasing peptides (GHRPs) like GHRP-2 and GHRP-6 is its exceptional selectivity. Earlier GHRPs, while effective at triggering GH release, also elevated other hormones — particularly cortisol and ACTH (the stress hormone pathway). This made them less ideal for clean research — you couldn't easily separate the effects of GH elevation from the confounding effects of elevated cortisol.
Ipamorelin was the first GHRP-receptor agonist shown to release growth hormone with a selectivity comparable to natural GHRH itself — without significantly affecting cortisol, prolactin, FSH, LH, or TSH plasma levels. In landmark research by Raun et al. published in the European Journal of Endocrinology, this lack of cortisol and ACTH elevation was documented even at doses more than 200-fold above the effective dose for GH release — a remarkably clean profile. View on PubMed →
In plain English: Ipamorelin tells the pituitary "release growth hormone right now" — through the ghrelin pathway — without also activating the stress hormone system that earlier GHRPs inadvertently triggered. Think of it as a precise key that opens only one lock rather than a master key that opens several.
Why Do Researchers Study Them Together?
This is where the science becomes genuinely interesting.
CJC-1295 and Ipamorelin activate two entirely separate receptor systems on the same target cells — the somatotroph cells of the anterior pituitary gland.
CJC-1295 activates the GHRH receptor → triggers a cascade that increases intracellular cAMP (cyclic adenosine monophosphate) → activates protein kinase A → enhances GH gene transcription and vesicle preparation.
Ipamorelin activates the GHS-R1a receptor → triggers a different cascade involving phospholipase C → mobilizes intracellular calcium → causes GH vesicle fusion and release.
These two pathways converge at the same somatotroph cell but through different molecular machinery. When both signals arrive simultaneously, the result is not additive — it is synergistic. Research has demonstrated that combined stimulation of both receptor pathways produces GH output significantly greater than the sum of what either compound achieves alone.
Think of it like a speaker system with two amplifiers instead of one. CJC-1295 turns up the volume on the GHRH channel. Ipamorelin turns up the volume on the ghrelin channel. When both channels run simultaneously into the same speaker — the pituitary somatotroph — the output is dramatically louder than either channel alone.
Additionally, Ipamorelin has been shown to suppress somatostatin — the body's own "stop" signal for GH release — further amplifying the combined GH response.
What Does the Research Show?
CJC-1295 Human Clinical Data
CJC-1295 has more published human clinical trial data than most research peptides in this category — making it one of the more thoroughly studied GHRH analogues available.
In a landmark randomized, placebo-controlled, double-blind human trial published in the Journal of Clinical Endocrinology & Metabolism, subcutaneous administration of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold for six days or more following a single injection. Mean plasma IGF-1 concentrations increased 1.5- to 3-fold and remained elevated for 9–11 days. The estimated half-life of CJC-1295 was 5.8–8.1 days. After multiple doses, mean IGF-1 levels remained above baseline for up to 28 days. No serious adverse reactions were reported. The authors concluded that CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-1 levels and was safe and relatively well tolerated. View on PubMed →
A follow-up study by Ionescu and Frohman published in the Journal of Clinical Endocrinology & Metabolism confirmed that CJC-1295 increased both trough and mean GH secretion and IGF-1 production — importantly, with preserved GH pulsatility. This finding is significant because maintaining the body's natural pulsatile GH release pattern is considered important for many of GH's physiological effects. Continuous flat-line GH elevation — as occurs with direct exogenous GH injection — bypasses this natural rhythm. CJC-1295 elevates the floor and ceiling of GH secretion while keeping the pulsatile architecture intact. View on PubMed →
Ipamorelin Research
Ipamorelin's most significant contribution to the research literature is its selectivity profile. The original pharmacological characterization by Raun et al. at Novo Nordisk — published in the European Journal of Endocrinology — established ipamorelin as the first growth hormone secretagogue to demonstrate selectivity for GH release comparable to natural GHRH. None of the GH secretagogues tested in the study affected FSH, LH, prolactin, or TSH plasma levels. Crucially, while other GHRPs like GHRP-2 and GHRP-6 produced significant elevations in ACTH and cortisol, ipamorelin did not — even at doses more than 200-fold above its effective GH-releasing dose. This profile makes ipamorelin the preferred GHRP for research contexts where clean mechanistic data is essential. View on PubMed →
Beyond growth hormone research, Ipamorelin's ghrelin receptor activity has also been studied in gastrointestinal contexts. A study by Greenwood-Van Meerveld et al. published in the Journal of Pharmacology and Experimental Therapeutics examined ipamorelin's effects in a rodent model of postoperative ileus — a condition involving impaired GI motility following surgery. Ipamorelin demonstrated a dose-dependent effect on improving gastric emptying and reversed the delayed gastrointestinal transit associated with postoperative ileus, suggesting that its ghrelin receptor activity has physiological relevance beyond the GH axis. View on PubMed →
The Synergistic Combination
A comprehensive review published in Translational Andrology and Urology examining growth hormone secretagogues in the management of body composition documented that treatment with GHS compounds can increase serum GH and IGF-1 levels comparable to those observed with recombinant GH therapy — while uniquely preserving the physiologic pulsatile GH secretion that exogenous GH therapy bypasses entirely. The reviewers specifically noted ipamorelin's selectivity profile as a key distinguishing characteristic among GHRPs for clinical research contexts. View on PubMed →
CJC-1295 + Ipamorelin vs. Other Growth Hormone Approaches
Understanding where this combination sits relative to other research approaches helps clarify why it has become so widely studied.
vs. Exogenous Growth Hormone (rGH) — direct GH injection delivers growth hormone from outside the body. This produces a non-pulsatile, sustained elevation that bypasses the body's own regulatory feedback. CJC-1295 + Ipamorelin instead stimulates the body's own pituitary to produce GH — preserving the natural pulsatile architecture and the feedback mechanisms that regulate it.
vs. GHRP-2 or GHRP-6 — older growth hormone-releasing peptides that also work through the ghrelin receptor but trigger significant cortisol and ACTH elevation at effective doses. Ipamorelin replaced these in most modern research protocols precisely because of its clean selectivity — only the GH axis is meaningfully activated.
vs. Sermorelin — another GHRH analogue with a shorter half-life than CJC-1295 and less data supporting its GH and IGF-1 elevation magnitude. CJC-1295 is generally considered the more potent GHRH analogue for research use.
Vitality Peptide Labs carries the full range of growth hormone research peptides. Researchers working with the growth hormone axis may also be interested in [MOTS-c →](MOTS-c 40mg) for mitochondrial and metabolic research, or [NAD+ →](NAD + 500mg) as a complementary longevity compound studied alongside GH axis research.
What the Research Doesn't Yet Tell Us
It is important to be honest about the current state of CJC-1295 and Ipamorelin research. While CJC-1295 has human clinical trial data — which places it ahead of most research peptides in terms of available evidence — the human data is primarily from small, short-term studies. Long-term safety data in humans is limited. Neither compound is FDA-approved for any therapeutic use.
CJC-1295's clinical development was halted following the death of a trial participant — though the attending physicians believed the most likely explanation was unrelated to the compound itself (pre-existing asymptomatic coronary artery disease). Development was discontinued as a precaution, which means the compound never progressed through the full FDA approval pathway.
Both compounds are listed on the World Anti-Doping Agency (WADA) prohibited list for competitive athletes.
For researchers working with CJC-1295 and Ipamorelin, compound purity and identity are critical variables. Both the GHRH receptor pathway and the ghrelin receptor pathway are sensitive enough that impure or mislabeled compounds would significantly compromise research integrity and could produce unpredictable results.
Shop CJC-1295 + Ipamorelin at Vitality Peptide Labs
Vitality Peptide Labs supplies research-grade CJC-1295 and Ipamorelin as lyophilized powder manufactured in GMP-certified facilities and verified by independent third-party Certificate of Analysis for purity and identity.
[Shop CJC-1295 + Ipamorelin →](CJC no DAC + Ipamorelin)
Researchers studying the growth hormone axis and longevity may also be interested in:
[MOTS-c →](MOTS-c 40mg) — mitochondrial-encoded metabolic regulator
[NAD+ →](NAD + 500mg) — mitochondrial energy and longevity research
[Epithalon →](Epithalon 50mg) — telomerase activation and anti-aging
[Retatrutide →](Retatrutide 30mg) — GLP-1/GIP/glucagon triple agonist
Research References
# | Title | Source |
1 | Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults | |
2 | Pulsatile Secretion of GH Persists During Continuous Stimulation by CJC-1295 | |
3 | Ipamorelin, the First Selective Growth Hormone Secretagogue | |
4 | Efficacy of Ipamorelin in a Rodent Model of Postoperative Ileus | |
5 | Beyond the Androgen Receptor: Growth Hormone Secretagogues in Body Composition Management |
This article is for educational and research purposes only. CJC-1295 and Ipamorelin are research compounds not approved for human use. Vitality Peptide Labs supplies research-grade peptides exclusively for laboratory research use. For questions about personal health, consult a licensed healthcare provider.
